Vera Therapeutics, Inc. Class A Common Stock (VERA) Stock Price
VERAStock
$27.88−8.62%52W
Market Cap$2.01B
P/E—
PEG Ratio—
Div yield—
Beta1.14
VERA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-47.06%
Price vs S&P 500 (4W)-17.27%
VGM Score52.10
VERA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$1.59 | -$1.52 | +4.45%(+$0.07) | |
| Q1 2026 | -$1.37 | -$1.69 | -23.00%(-$0.32) | |
| Q4 2025 | -$1.27 | -$1.39 | -9.74%(-$0.12) | |
| Q3 2025 | -$1.13 | -$1.26 | -11.74%(-$0.13) | |
| Q2 2025 | -$0.62 | -$1.20 | -94.77%(-$0.58) |
VERA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
VERAVera Therapeutics, Inc. Class A Common Stock | — | — | C | — | — | — | — | $27.88 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Vera Therapeutics, Inc. Class A Common Stock
Vera Therapeutics is a clinical-stage biotech company developing atacicept, a once-weekly subcutaneous fusion protein designed to treat serious autoimmune diseases. The drug works by blocking two key drivers of autoimmune dysfunction—B lymphocyte stimulator and APRIL—which reduces B cell and plasma cell activity and autoantibody production. The company is advancing atacicept through clinical development with a focus on transformative therapeutic potential in immunological disorders.